Clinical trial

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01253369

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-06-01

PhasePHASE2

Study timeline

Study start (unknown)2010-06-01Date precision: month

Registry last updated2019-04-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancerunresolved

Lung Cancerunresolved

SCLCunresolved

Interventions

PazopanibDRUG · verified · RxNorm: pazopanib

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

Massachusetts General Hospitalcollaborator

Brigham and Women's Hospitalcollaborator

Beth Israel Deaconess Medical Centercollaborator

GlaxoSmithKlinecollaborator

Mapped research locations

BostonMassachusetts, United States3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01253369 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.